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1. Introduction  
Rheumatoid arthritis (RA) is the most common form of inflammatory arthritis in adults and 
is characterized by chronic, progressive, systemic inflammation leading to substantial pain, 
disability, and other morbidities1. Osteoporosis (OP) is more frequent in patients with RA 
than in the general population due to active systemic inflammation as well as the use of 
corticosteroids and immobility. OP is characterized by low bone mass, and 
microarchitectural deterioration of bony tissue, with a consequent increase in bone fragility 
and susceptibility to fractures. According to the WHO criteria (Tab. 1), osteoporosis can also 
be defined as a value of bone mineral density (BMD) more than - 2.5 standard deviations 
below the young normal mean. Subsequent disability may lead to loss of independence and 
quality of life. Underlining the clinical significance of BMD in RA, the risk of hip2 and 
vertebral fractures3 and the associated morbidity, mortality and healthcare costs are 
increased in patients with RA (Fig.1). 
T - Score Diagnosis
0 to > -1 Normal bone density
-1 to >-2,5 Osteopenia
<  -2,5 Osteoporosis
< -2,5 with fracture Severe osteoporosis
Table 1. WHO T-score criteria for Bone Mineral Density 
Localized bone loss in the form of bone erosions and periarticular osteopenia constitutes an 
important radiographic criterion for the diagnosis of RA. In addition, generalized bone loss 
has been demonstrated in RA, systemic lupus erythematosus, and ankylosing spondylitis in 
several observational and some longitudinal studies using markers of bone turnover, bone 
histomorphometry, and bone densitometry4.  
                                                 
1 Pattison DJ, Harrison RA, Symmons DP. The role of diet in susceptibility to rheumatoid arthritis: a 
systematic review. J Rheumatol. 2004;31(7):1310-9. 
2 Cooper C, Coupland C, Mitchell M. Rheumatoid arthritis, corticosteroid therapy and hip fracture. Ann 
Rheum Dis 1995;54:49–52.  
3 Arai, T. & Kragic, D. Van Staa TP, Geusens P, Bijlsma JWJ, Leufkens HGM, Cooper C. Clinical 
assessment of the long-term risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum 
2006;54:3104–12.  
4 Eggelmeijer F, Papapoulos SE, Westedt ML, Van Paassen HC, Dijkmans BA, Breedveld FC: Bone 
metabolism in rheumatoid arthritis; relation to disease activity. Br J Rheumatol 1993, 32: 387-391.  
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Fig. 1. In osteoporosis, the cortex becomes thinner and more brittle, while the inner 
trabecular bone develops larger holes 
OP occurs in two forms during the course of the AR5: 
1. periarticular osteopenia in close proximity to inflamed joints, which is a typical 
phenomenon in early and prolonged rheumatoid disease;  
2. generalized osteoporosis, which affects the axial and appendicular bones. Inflammation 
has the effect of provoking more severe and accelerated bone loss in the hand as 
compared with hip and spine. 
In all inflammatory diseases, use of glucocorticoids (GC) is a common therapy. There is no 
doubt about the deleterious effect of GC in bone metabolism, suppressing bone formation 
and enhancing bone resorption. The addition of GC to osteoprogenitor cells in vitro actually 
increases their bone-forming capacity but it also increases apoptosis of mature osteoblasts 
and osteocytes and therefore affects capacity of bone formation. This potent anti-
inflammatory drug reduces production of pro-inflammatory cytokines (IL-1, IL-6, and TNF-
ǂ), but provokes bone resorption by increasing the synthesis of RANKL and inhibiting OPG 
production with consequent induction of osteoclastogenesis6. 
Systemic inflammation and GC use accelerates bone loss independent of other risk factors7 
but other factors must be valorized. Immobilization due to pain from inflamed joints, 
impairment of physical activity, reduced calcium intake, and poor nutrition associated with 
enhanced basal energy expenditure are also risk factors related to low BMD, common is this 
population. In children, delayed puberty and stunted growth can adversely affect bone 
remodeling8. 
                                                 
5 Sambrook PN: The skeleton in rheumatoid arthritis: common mechanism for bone erosion and 
osteoporosis? J Rheumatol 2000, 27:2541-2542. Gregório LH, Lacativa PG, Melazzi AC, Russo LA.  
6 Glucocorticoid-induced osteoporosis. Arq Bras Endocrinol Metab. 2006;50(4):793-801. 
7 Roldán JF, Del Rincón I, Escalante A. Loss of cortical bone from the metacarpal diaphysis in patients 
with rheumatoid arthritis: independent effects of systemic inflammation and glucocorticoids. J 
Rheumatol. 2006;33(3):508-16. 
8 Viswanathan A, Sylvester FA. Chronic pediatric inflammatory diseases: effects on bone. Rev Endocr 
Metab Disord. 2008;9(2):107-22.  
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Consequently, increase in bone resorption, both focal and systemic, are common in patients 
with RA. In patients with active RA compared to matched controls and patients with 
inactive RA serum osteocalcin which reflects bone formation was found to be significantly 
lower and crosslinked N-telopeptidases of type 1 collagen (NTX) and deoxypyridinoline 
(DPD) which reflect bone resorption, were significantly higher. There were positive 
correlations between these bone markers and disease activity9. 
2. Epidemiology and prevalence 
Rheumatoid arthritis is a chronic inflammatory and destructive joint disease that affects 0.5-
1% of the world’s population and commonly leads to significant disability and consequent 
impairment of quality of life10. It is two or three times more frequent in women than in men 
and can start at any age, with its peak incidence between the fourth and sixth decades of 
life11. Generalized osteoporosis is an extra-articular complication of rheumatoid arthritis that 
results in increased risk of fractures and associated morbidity, mortality, and healthcare 
costs. The incidence of osteoporosis among patients with rheumatoid arthritis is 15-20% at 
the hip and spine12. Haugeberg elegantly showed a twofold increase in osteoporosis in 
women with RA and a twofold increase of reduced bone mass in men with RA, compared 
with patients without RA in a population based study13. Italian research, performed with 
patients with established RA, reported disease-related factors, such as long disease duration, 
high disease activity, joint damage, functional disability and corticosteroid use, as 
determinants of osteoporosis or reduced BMD14 . Hence, patients with long-standing RA 
with destructive disease, functional disability or immobilisation, or who are on longterm 
corticosteroid treatment are at high risk for osteoporosis15. This could be explained by the 
fact that generalised osteoporosis is more associated with long-standing, destructive and 
disabling RA,whereas early RA is associated with periarticular osteoporosis. This is further 
supported by the fact that longer symptom duration is independently associated with more 
generalised osteoporosis in studies. 
                                                 
9 Seriolo B, Ferretti V, Sulli A, Caratto E, Fasciolo D, Cutolo M. Serum osteocalcin levels in 
premenopausal rheumatoid arthritis patients. Ann N Y Acad Sci. 2002;966:502-7. 
10 Brandão L, Ferraz MB, Zerbini CAF. Avaliação da qualidade de vida na artrite reumatóide: revisão 
atualizada [Evaluation of quality of life in rheumatoid arthritis]. Rev Bras Reumatol. 1997;37(5):275-81. 
11 Gabriel SE. The epidemiology of rheumatoid arthritis. Rheum Dis Clin North Am. 2001;27(2):269-81. 
Martin JC, Munro R, Campbell MK, Reid DM. Effects of disease and corticosteroids on appendicular 
bone mass in postmenopausal women with rheumatoid arthritis: comparison with axial measurements. 
Br J Rheumatol. 1999;36(1):43-9.  
12 Lodder MC, Haugeberg G, Lems WF, et al. Radiographic damage associated with low bone mineral 
density and vertebral deformities in rheumatoid arthritis: the Oslo-Truro-Amsterdam (OSTRA) 
collaborative study. Arthritis Rheum. 2003;49(2):209-15.  
13 Haugeberg G, Uhlig T, Falch JA, Halse JI, Kvien TK. Reduced bone mineral density in male 
rheumatoid arthritis patients: frequencies and associations with demographic and disease variables in 
ninety-four patients in the Oslo County Rheumatoid Arthritis Register. Arthritis Rheum 2000;43:2776–84. 
14 Sinigaglia L, Nervetti A, Mela Q, Bianchi G, Del Puente A, Di Munno O, et al. A multicenter cross 
sectional study on bone mineral density in rheumatoid arthritis. Italian Study Group on Bone Mass in 
Rheumatoid Arthritis. J Rheumatol 2000;27:2582–9.  
15 Lems WF, Dijkmans BAC. Should we look for osteoporosis in patients with rheumatoid arthritis? Ann 
Rheum Dis 1998;57:325–7.  
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Numerous studies have investigated the relation between demographic and disease related 
variables on the one hand, and bone mass on the other, in patients with RA. These studies 
tried to identify patients at high risk of osteoporosis16. Studies investigating the variables 
associated with BMD17 showed some inconsistencies, which might be caused by differences 
in methodological aspects, such as sample size and patient selection. Moreover, the complex 
interaction between inflammation, immobility, and corticosteroid use may contribute to the 
lack of unanimous results. 
Only a few studies focusing on BMD in patients with early RA have been performed; 
however the disease duration in some was up to 5 years18. Very little is known about the 
extent of osteoporosis and the influence of disease-associated factors on BMD in patients 
with recently diagnosed RA19. These data are required in order to unravel the common 
mechanisms between generalised osteoporosis and RA. 
Symptom duration and the presence of RF were the only RAspecific markers for 
osteoporosis and reduced BMD in this study. It is known that seropositive RA is associated 
with more aggressive joint disease and is more commonly complicated by extra-articular 
manifestations than is seronegative RA20 21. Previous studies showed an independent 
association between the presence of RF and osteoporosis or reduced BMD in established and 
recent onset RA. 
3. Etiology and pathophysiology 
3.1 Bone remodeling  
Throughout life, normal skeletal maintenance occurs by a tightly coupled process of bone 
remodeling. It consists of a sequential process of bone resorption by osteoclasts followed by 
deposition of new bone by osteoblasts. Osteoblasts are derived from precursor cells that can 
also be stimulated to become muscle, fat or cartilage; however, under the right conditions 
these cells change (or differentiate) to form new bone, producing the collagen that forms the 
scaffolding or bone matrix. This calcium- and phosphate-rich mineral is added to the matrix 
to form the hard, yet resilient, tissue that is healthy bone. The osteoclasts remove bone by 
dissolving the mineral and breaking down the matrix in a process that is called bone 
resorption. The osteoclasts come from the same precursor cells in the bone marrow that 
                                                 
16 Martin JC, Munro R, Campbell MK, Reid DM. Effects of disease and corticosteroids on appendicular 
bone mass in postmenopausal women with rheumatoid arthritis: comparison with axial measurements. 
Br J Rheumatol 1997;36:43–9.  
17 Kroot EJ, Nieuwenhuizen MG, Waal Malefijt MC, van Riel PL, Pasker-de Jong PC, Laan RF. Change in 
bone mineral density in patients with rheumatoid arthritis during the first decade of the disease. 
Arthritis Rheum 2001;44:1254–60. 
18 Shenstone BD, Mahmoud A, Woodward R, Elvins D, Palmer R, Ring F, et al. Bone mineral density in 
nonsteroid treated early rheumatoid arthritis. Ann Rheum Dis 1994;53:681–4. 
19 Keller C, Hafstrom I, Svensson B. Bone mineral density in women and men with early rheumatoid 
arthritis. Scand J Rheumatol 2001;30:213–20.  
20 Egeland T, Munthe E. The role of the laboratory in rheumatology. Rheumatoid factors. Clin Rheum Dis 
1983;9:135–60. 22. 
21 Van Zeben D, Hazes JM, Zwinderman AH, Cats A, van der Voort EA, Breedveld FC. Clinical 
significance of rheumatoid factors in early rheumatoid arthritis: results of a follow up study. Ann Rheum 
Dis 1992;9:1029–35. 
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produce white blood cells. These precursor cells can also circulate in the blood and be 
available at different sites in need of bone breakdown. Osteoclasts are formed by fusion of 
small precursor cells into large, highly active cells with many nuclei. Removal and 
replacement of bone in the remodeling cycleis controlled by local and systemic factors that 
regulate bone remodeling to fulfill both its structural and metabolic functions. The 
activation of this process involves an interaction between cells of the osteoblastic lineage 
and the precursors that will become osteoclasts. The differentiation of myeloid progenitor 
cells into committed osteoclast lineage is characterized by the appearance of the mRNA and 
protein for vitronectin receptor, cathepsin K, tartrate-resistant acid phosphatase, and 
calcitonin receptor22 23.This process of osteoclastogenesis requires the presence of receptor 
activator of nuclear factor-B ligand (RANKL; also known as OPGL, TRANCE, ODF, and 
SOFA) and the permissive factor, macrophage colony stimulating factor (M-CSF) secreted 
by the local osteoblast/stromal cells. RANKL binds to its receptor RANK expressed on the 
surface of osteoclast precursor cells and stimulates their differentiation into mature 
osteoclasts24. The osteoblast/stromal cells also secrete osteoprotegerin (OPG; also known as 
OCIF, TR-1, FDCR-1, and TNFRSF-11B), a soluble decoy receptor protein that binds to 
RANKL and prevents its binding to RANK on the preosteoclast cells. The biologic effects of 
OPG are, therefore, the opposite of those of RANKL, i.e. OPG inhibits osteoclastogenesis 
and osteoclast function and promotes osteoclast apoptosis25. The production and activity of 
both RANKL and OPG are influenced by several cytokines, inflammatory mediators, and 
calcitropic hormones that ‘converge’ onto these proteins. The net RANKL/OPG balance 
determines the differentiation, activation, and survival of osteoclasts, which in turn 
determine bone loss26. 
3.2 Focal bone erosion in rheumatoid arthritis: The role of the rank/rankl/OPG system 
and the TNF-α 
Although the mechanisms of cartilage destruction in rheumatoid arthritis (RA) are well 
described, the mechanisms responsible for bone erosion in this disease have only recently 
been studied. The role of osteoclasts in bone erosion in RA has been suspected for many 
years on the basis of indirect evidence, including the identification of multinucleated cells 
with phenotypic features of osteoclasts at sites of erosion in human RA27 28.  
                                                 
22 Lee SK, Goldring SR, Lorenzo JA: Expression of the calcitonin receptor in bone marrow cell cultures 
and in bone: a specific marker of the differentiated osteoclast that is regulated by calcitonin. 
Endocrinology 1995, 136:4572-4581.  
23 Faust J, Lacey DL, Hunt P, Burgess TL, Scully S, Van G, Eli A, Qian Y, Shalhoub V: Osteoclast markers 
accumulate on cells developing from human peripheral blood mononuclear precursors. J Cell Biochem 
1999, 72:67-80. 
24 Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR. Osteoprotegerin ligand is a cytokine that 
regulates osteoclast differentiation and activation. Cell 1998, 93:165-176.  
25 Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS. Osteoprotegerin: a novel secreted protein 
involved in the regulation of bone density. Cell 1997, 89:309-319.  
26 Suda T, Takahashi N, Martin TJ: Modulation of osteoclast differentiation. Endocr Rev 1992, 13:66-80.  
27 Gravallese EM, Harada Y, Wang JT, Gorn AH, Thornhill TS, Goldring SR. Identification of cell types 
responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis. Am J Pathol 
1998;152:943–51. 
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Inflammation modulates bone resorption mainly by two mechanisms. Firstly, pro-
inflammatory cytokines have a final common mediator of osteoclast function: receptor 
activator of nuclear factor-B (RANK) and its functional ligand (RANKL), also known as 
TRANCE (TNF-related activation induced cytokine)29 30. Secondly, osteoclastogenesis can be 
regulated through the modulation of macrophage colony stimulating factor (M-CSF). 
RANKL is a membrane-bound tumor necrosis factor (TNF) receptor expressed on 
osteoblast precursor cells that recognize RANK on the osteoclast surface through a direct 
cell-cell interaction. This process is essential for osteoclast differentiation, activation and 
survival. RANKL is considered the key osteoclastogenic cytokine as the RANKL-RANK 
interaction stimulates several transcription factors and all three families of MAP kinases31. 
The osteoblast/stromal cells also secrete osteoprotegerin (OPG), a soluble decoy receptor 
protein that binds to RANKL and prevents its binding to RANK on the preosteoclast cells. 
The biologic effects of OPG are, therefore, the opposite of those of RANKL; infact, it 
inhibits osteoclastogenesis and osteoclast function and promotes osteoclast apoptosis32. 
The net RANKL/OPG balance determines the differentiation, activation, and survival of 
osteoclasts, which in turn determine bone loss33. Synovial tissues provide a source of 
RANKL that could influence osteoclastogenesis. Synovial fibroblasts from patients with 
RA produce mRNA   and protein for RANKL. RANKL is also expressed by T lymphocytes 
from RA synovial tissues34. Adjuvant-induced arthritis (AIA) is an animal model of T 
lymphocyte mediated inflammatory arthritis characterized by destruction of bone and 
cartilage similar to that in RA. In this model, activated T cells express RANKL protein on 
their surface, and through binding of RANKL to RANK on preosteoclasts, these cells 
promote osteoclastogenesis and subsequent bone loss. Co-culture experiments using RA 
synovial fibroblasts and peripheral blood mononuclear cells as a source of osteoclast 
precursors demonstrate that osteoclast-like cells are generated, and the generation of 
these cells is inhibited by the addition of OPG (Fig.2) Similarly, activated T cells 
expressing RANKL induce osteoclasts from autologous peripheral blood monocytes, a 
process that is also inhibited by OPG35.  
                                                                                                                            
28 Suzuki Y, Nishikaku F, Nakatuka M, Koga Y. Osteoclast-like cells in murine collagen induced 
arthritis. J Rheumatol 1998;25:1154–60.  
29 Romas E, Bakharevski O, Hards DK, Kartsogiannis V, Quinn JMW, Ryan PFJ, et al. Expression of 
osteoclast differentiation factor at sites of bone erosion in collagen-induced arthritis. Arthritis Rheum 
2000;43:821–6. 
30 Leisen JCC, Duncan H, Riddle JM, Pitchford WC. The erosive front: a topographic study of the 
junction between the pannus and the subchondral plate in the macerated rheumatoid metacarpal head. 
J Rheumatol 1988;15:17–22.  
31 Mundy GR. Osteoporosis and inflammation. Nutr Rev. 2007;65(12 Pt 2):S147-51 
32 Teitelbaum SL. Osteoclasts: what do they do and how do they do it? Am J Pathol. 2007;170(2):427-35.  
33 Takayanagi H, Iizuka H, Juji T, Nakagawa T, Yamamoto A. Involvement of receptor activator of 
nuclear factor kappa-B ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes 
in rheumatoid arthritis. Arthritis Rheum 2000;43:259–69.  
34 Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A. Activated T cells regulate bone loss and joint 
destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999;402:304–9. 
35 Suzuki Y, Tsutsumi Y, Nakagawa M, Suzuki H, Matsushita K, Beppu Ml. Osteoclast-like cells in an in 
vitro model of bone destruction by rheumatoid synovium. Rheumatology (Oxford) 2001;40:673–82. 
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Fig. 2. A schematic overview of the RANK/RANKL/OPG system 
Synovial tissues may also provide a source of osteoclast precursor cells, as macrophages 
isolated from RA synovial tissues differentiate into osteoclasts in the presence of M-CSF 
plus RANKL. More recent studies have extended these findings. Cells digested from RA 
synovial tissue samples generate TRAP positivemultinucleated cells that form resorption 
pits on dentine slices36 a definitive demonstration that these cells are osteoclasts. Synovial 
fibroblasts in rheumatoid synovium may also contribute significantly to localized bone loss. 
These cells produce chemokines such as macrophage inflammatory peptide 1, regulated-
upon-activation normal T cell expressed and secreted, IL-8, and IL-16, which promote 
lymphocyte infiltration and support lymphoproliferation via secretion of various colony-
stimulating factors37. This results in a large pool of RANKL-expressing lymphocytes 
supporting osteoclastogenesis and local bone loss. Furthermore, synovial fibroblasts may 
directly contribute to local bone destruction by expressing RANKL on their surface38 and by 
secreting cathepsins. Elevated levels of tumor necrosis factor (TNF)-a have been 
demonstrated by immunoassays in several inflammatory arthritides. TNF-a promotes 
expression of adhesion molecules, activation of leukocytes, recruitment of leukocytes, and 
production of proinflammatory cytokines (e.g. IL-1, IL-6, and IL-8) in RA. There are two 
mechanisms by which TNF-ǂ acts in osteoclasts, both marrow stromal cells and osteoclast 
                                                 
36 Kontoyiannis D, Kollias G: Fibroblast biology: synovial fibroblasts in rheumatoid arthritis: leading 
role or chorus line? Arthritis Res 2000, 2:342-343. 
37 Ross FP, Chappel J, Alvarez JI, Sander D, Butler WT, Farach-Carson MC. Interactions between the 
bone matrix proteins osteopontin and bone sialoprotein and the osteoclast integrin alpha v beta 3 
potentiate bone resorption: J Biol Chem 1993, 268:9901-9907. 
38 Teitelbaum SL. Osteoclasts: what do they do and how do they do it? Am J Pathol. 2007;170(2):427-35.  
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precursors express TNF-ǂ receptors. The main process occurs when stromal cells are 
exposed to TNF-ǂ and produce RANKL, M-CSF, and IL-1, which promote osteoclast 
formation and activation. TNF-ǂ and RANKL are synergistic, and minimal levels of one 
markedly enhances the osteoclastogenic capacity of the other39 (Fig. 3).  
 
Fig. 3. Activated human T cells induce osteoclastogenesis from human monocytes 
TNF-ǂ also has potent antiapoptotic effects on osteoclasts, prolonging their lifespan40. The 
second mechanism occurs when the inflammatory process becomes more aggressive and 
TNF-ǂ may promote osteoclast formation by directly stimulating its precursors in the 
absence of stromal cells responsive to the cytokine, perhaps through activation of 
transforming growth factor (TGF)-ǃ. 
3.3 Focal bone erosion in rheumatoid arthritis: The role of the glucocorticoid use 
In all inflammatory diseases, use of glucocorticoids (GC) is a common therapy. The use of 
GC, however, is associated with a variety of adverse effects,1 including the development of 
osteoporosis and fractures. In patients who have received GCs for longer than six months, 
the estimated glucocorticoid-induced osteoporosis (GIO) frequency is 50%41. The 
pathogenesis of GIO is multifaceted. Glucocorticoids have indirect effects on osteoporosis by 
inhibiting calcium absorption from the gastrointestinal track and decreasing the renal 
tubular reabsorption of calcium and consequentely secondary hyperparathyroidism. GCs 
                                                 
39 Weitzmann MN, Pacifici R. The role of T lymphocytes in bone metabolism. Immunol Rev. 2005;208:154-
68.  
40 Van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid induced osteoporosis: a 
meta-analysis. Osteoporos Int. 2002;13:777- 87.  
41 Pereira RM, Delany AM, Canalis E. Cortisol inhibits the differentiation and apoptosis of osteoblasts in 
culture. Bone 2001;28:484-90. 
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reduce growth hormone (GH) secretion and may alter the GH/insulin-like growth factor 
(IGF)-I axis. An important role may be played by skeletal IGF-I because GCs inhibit IGF-I 
transcription in osteoblasts. Glucocorticoids have direct effects on bone cells. GCs reduce the 
replication, differentiation and function of osteoblasts42 and increase the apoptosis rates of 
mature cells, thereby depleting the osteoblastic cell population and inhibiting the function of 
mature cells. Furthermore, in the presence of GCs, bone marrow stromal cells do not 
differentiate into osteoblasts; instead, these cells differentiate toward an adipocyte cell 
lineage. Moreover, GCs induce apoptosis in osteocytes and affect the functioning of these 
cells. GCs increase the expression of M-CSF and receptor activator of RANK-L. In addition, 
GCs decrease the expression of osteoprotegerin in stromal and osteoblastic cells. Through 
these mechanisms, GCs can induce the formation of osteoclasts and favor bone resorption. 
GCs also reduce the rate of apoptosis among mature osteoclasts. 
4. Diagnosis 
The initial evaluation of secondary osteoporosis should include a detailed history of clinical 
risk factors for fractures and the underlying medical conditions and medications that cause 
bone loss, a thorough physical. Patients with decreased bone density usually have no 
specific abnormal physical findings. Those with vertebral compression fractures will have 
kyposis, protruding abdomen and height loss. Back tenderness is usually only present after 
an acute fracture. Gait speed and grip strength are often reduced in patients who have or are 
about to have a hip fracture. Visual acuity should be checked in geriatric patients because it 
is a risk factor for falling. 
Based on these initial findings and the clinical index of suspicion, further laboratory and 
imaging studies as well as invasive tests are required. examination and laboratory. 
Optimal evaluation consists of establishing the diagnosis of osteoporosis on the basis of 
bone mass assessment (BMD), establishing the fracture risk, and determining the need for 
therapy. Dual-energy x-ray absorptiometry (DXA) is the preferred technique to measure 
BMD, and is the technique used at most centers43. The hip and the spine  are the preferred 
site for BMD measurement due to the high predictive value of hip BMD for fracture risk. 
The World Health Organization (WHO) has established the following operational 
definition for osteoporosis based on BMD as measured by DXA (Fig. 4), commonly 
expressed as a T-score.  
The World Health Organization (WHO) has established criteria for making the diagnosis of 
osteoporosis, as well as determining levels that predict higher chances of fractures. These 
criteria are based on comparing the BMD of the patient with that of a typical healthy, young 
female's. BMD values that fall well below the average for the healthy, young female's (stated 
statistically as 2.5 standard deviations below the average) are diagnosed as osteoporotic. If a 
patient has a BMD value less than the healthy, young female, but not 2.5 standard 
deviations below the average, the bone is osteopenic. Osteopenic means decreased bone 
mineral density, but it's not as severe as osteoporosis.  
                                                 
42 Khan AA, Hanley DA, Bilezikian JP, Binkley N, Brown JP. Standards for performing DXA in 
individuals with secondary causes of osteoporosis. Journal of Clinical Densitometry 2006 9 47–57. 
43 Heaney RP. Thinking straight about calcium. N Engl J Med 1993; 328:503-505.  
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Fig. 4. A scanner used to measure bone density with Dual Energy X-ray absorptiometry.  
Although these criteria are widely used, they were based on a Caucasian female, so there 
will be some differences when these levels are applied to non-Caucasian females or to males 
in general. Despite this flaw, BMD measurement is a common method that's helpful in all 
groups. Laboratory evaluation for secondary causes of osteoporosis should be considered 
when osteoporosis is diagnosed. Serum calcium, phosphorus, alkaline phosphatase, 
creatinine, vitamin D, complete blood count and thyroid stimulating hormone (TSH) levels 
are usually sufficient baseline tests. Further laboratory tests can be done as clinically 
appropriate, such as parathyroid hormone level, urine free cortisol, liver function tests, or 
serum immune electrophoresis. Biochemical indices of skeletal turnover could potentially be 
helpful in the diagnosis and monitoring of therapy.  
5. Treatment 
The treatment of inflammatory bone loss can be aimed at attempts to suppress bone 
resorption and to increase bone formation.  
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5.1 Calcium and vitamin D 
Both alfacalcidol (25 OH vitamin D3) and calcitriol (1,25 (OH)2 Vitamin D3) are used by 
some for the treatment of osteoporosis44. An adequate intake of calcium and  Vitamin D 
supplementation are recommended as vitamin D. Serum and urinary calcium, serum 
25OHD, and PTH concentrations should be used to evaluate hypovitaminosis D, secondary 
hyperparathyroidism and low net calcium balance. In randomized trials, the use of calcium 
and vitamin D alone had no significant benefit in bone density. However, these disturbances 
usually found in inflammatory diseases should be corrected to avoid the interference with 
anti-osteoporotic treatment efficacy. Calcium intake (from diet, added to supplementation) 
must be at least 1,200 mg/d, and vitamin D supplementation should be at least 800 UI/d if 
any of those disturbances are found. In addition, the efficacy of anti-osteoporotic drugs has 
only been demonstrated in the presence of vitamin D and calcium supplementation. 
Therapy should be titrated with doses that result in normocalcemia and serum 25-
hydroxyvitamin D concentrations of at least 30 ng/ml. In patients with normal renal 
function, a decrease in serum PTH levels from elevated to normal levels indicates that 25-
hydroxyvitamin D deficiency has been corrected. Some anti-epileptic drugs, e.g. phenytoin, 
phenobarbitone, primidone, and carbamazepine, increase hepatic metabolism of vitamin D, 
requiring higher vitamin D doses.  
5.2 Bisphosphonates 
Bisphosphonates have a strong affinity for bone apatite, which is the basis for their clinical 
use. They are potent inhibitors of bone resorption and produce their effect by reducing the 
recruitment and activity of osteoclasts and increasing their apoptosis. In general, 
alendronate (70 mg/week) and risedronate (35 mg/week) are reasonable antiosteoporotic 
drugs for secondary osteoporosis. However, many patients with osteoporosis secondary to 
gastrointestinal diseases or concurrent medications not tolerating, or adhering to, oral 
bisphosphonates and those in whom oral bisphosphonates are contraindicated may benefit 
from treatment with i.v. ibandronate or zoledronic acid. Many studies have shown that 
Alendronate and Zoledronate are able to reduce joint swelling and blood inflammatory tests 
(IL-1, IL-6, TNF-ǂ, b2-microglobulin and erythrocyte sedimentation rate and C-reactive 
protein values) in various experimental arthritis animal models and in human studies. These 
medications reduce the macrophage production of TNF-ǂ, IL-1 and nitric oxide (NO) and 
induce apoptosis of monocyte-macrophage-derived cell lines. These effects are in part 
dependent on RANKL inhibition and in part dependent on cytoplasmic events which 
involve protein-kinase C and iron ions. All these effects explain why, although 
bisphosphonates enhance proliferation of T-lymphocytes, they have been successfully used 
to treat bone loss secondary to RA45. The overall safety profile of bisphosphonates is 
favorable. Oral bisphosphonates are associated with mild gastrointestinal disturbances, and 
rarely cause esophagitis and ulcer. A recent study also showed an increase in esophageal 
cancer among chronic users. Intravenous zolendronate can induce a transient acute phase 
                                                 
44 Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA. Effect of parathyroid hormone (1-34) on 
fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 
2001;344:1434–4.  
45 Ahrader SP, Raggucci KR. Parathyroid hormone (1-84) and treatment of osteoporosis. Ann 
Pharmacother. 2005;39:1511–6. 
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reaction with fever, bone and muscle pain that ameliorates or disappears after subsequent 
courses. Osteonecrosis of the jaw has been described in cancer patients receiving high doses 
of intravenous pamidronate or zoledronate. Atrial fibrillation was noted to occur in a higher 
frequency after intravenous zolendronate, but a cause-effect relationship was not 
established and it was not seen in another study.  
5.3 Teriparatide 
Intermittent administration of PTH (for example, with daily subcutaneous injections) results 
in an increase of the number and activity of osteoblasts, leading to an increase in bone mass 
and in an improvement in skeletal architecture at both cancellous and cortical skeletal sites. 
The 1-34 N-terminal fragment (teriparatide) is used for the management of osteoporosis. 
Treatment with teriparatide has been shown to reduce significantly the risk of vertebral 
fractures and to reduce non-vertebral but not hip fractures46.The recommended dose is 20 
μg of teriparatide daily, given as a subcutaneous injection. The effect was initially seen in 
patients with severe osteoporosis and established vertebral fractures. Efficacy was later 
shown with osteoporosis even without fractures47.  
5.4 Stronzium ranelate 
Strontium ranelate is a recently approved agent in Europe, for the treatment of 
postmenopausal osteoporosis, to reduce the risk of vertebral and hip fractures (49). There is 
some evidence that strontium ranelate both inhibits bone resorption and stimulates bone 
formation, suggesting that the agent may uncouple the bone remodelling process. The 
recommended daily dose is a one 2-gram sachet once daily by mouth. The absorption of 
strontium ranelate is reduced by food, milk and its derivative products and the drug should 
be administered, therefore, between meals. Ideally, it should be taken at bedtime, preferably 
two hours after eating. Strontium ranelate is not recommended for patients with severe 
renal impairment (creatinine clearance below 30 mL/min).  
5.5 Denosumab 
Denosumab, a new drug under evaluation, acts as an anti-RANKL blocking osteoblast 
differention and slowing bone resorption similar to the OPG. Denosumab is a fully human 
monoclonal antibody that mimics the activity of osteoprotegerin. It binds to RANKL, 
thereby preventing RANKL from interacting with RANK and reducing its bone resorption.  
5.6 Raloxifene 
Raloxifene is part of Selective Estrogen Receptor Modulators (SERMs). They are a class of 
medications that act on the estrogen receptors throughout the body in a selective manner. 
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Normally, bone mineral density (BMD) is tightly regulated by a balance between osteoblast 
and osteoclast activity in the trabecular bone. Estrogen has a major role in regulation of the 
bone formation-resorption equilibrium, as it stimulates osteoblast activity48. Some SERMs 
such as raloxifene, act on the bone by slowing bone resorption by the osteoclasts. Raloxifene 
has the added advantage of reducing the risk of invasive breast cancer.  
6. Therapy in glucocorticoid treatment 
There are a number of guidelines regarding the management of GIO in patients who are 
receiving glucocorticoid treatment or that will be starting this therapy. We have analyzed 
the guidelines established by the American College of Rheumatology (ACR)49, and the 
Dutch Society of Rheumatology (DSR)50. A Cochrane Database Meta-Analysis concluded 
that calcium and vitamin D supplementation should be started in all patients who are 
administered glucocorticoids because of their low toxicity, low cost and the possible benefit 
in terms of fracture risk51. Vitamin D is a hormone that increases intestinal calcium 
absorption and increases its reabsorption in distal renal tubules. Serum levels of at least 30 
ng/mL (82 nmol/L), and optimally of 40–60 ng/mL, of 25-hydroxyvitamin D should be the 
target treatment regimen for GIO management. To achieve these levels, 1,000 to 2,000 IU of 
oral vitamin D daily may be necessary52. Bisphosphonates are indicated for the prevention 
and treatment of GIO and most guidelines recommend the use of these drugs. The 
prevention and treatment goals of bisphosphonate use are stabilized or increased bone 
mineral density, as well as reduced frequency of fractures. A study using risedronate 
showed a decrease in vertebral fractures after one year of treatment53. Currently, 
alendronate (70 mg/ week or 10 mg/day) and risedronate (35 mg/week or 5 mg/ day) are 
the only oral antiresorptive drugs that are recommended in GIO. Recently, zoledronic acid 
was approved for the prevention and treatment of GIO. In a multicenter, double-blind, 
double-dummy, randomized controlled trial that included 833 patients, a single 5 mg 
intravenous infusion of zoledronic caused a greater increase in bone mineral density than 
oral risedronate at 5 mg daily54. Bisphosphonate treatment is recommended while patients 
                                                 
48 Meunier PJ, Vignot E, Garnero P. "Treatment of postmenopausal women with osteoporosis or low 
bone density with raloxifene. Raloxifene Study Group". Osteoporos Int 1999;10 (4): 330–36. 
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Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 
update. Arthritis Rheum. 2001;44:1496-503. 
50 Geusens PP, de Nijs RN, Lems WF, Laan RF, Struijs A, van Staa TP, et al. Prevention of glucocorticoid 
osteoporosis: a consensus document of the Dutch Society for Rheumatology. Ann Rheum Dis. 2004; 
63:324-5. 
51 Berris KK, Repp AL, Kleerekoper M. Glucocorticoid-induced osteoporosis. Curr Opin Endocrinol 
Diabetes Obes. 2007;14:446-50. 
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54 Reid DM, Devogelaer JP, Saag K, Roux C, Lau CS, Reginster JY, et al. Zoledronic acid and risedronate 
in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, 
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are on glucocorticoids; however, in subjects with significant bone loss, therapy may need to be 
continued following the discontinuation of glucocorticoids. Caution needs to be exercised 
when considering the use of bisphosphonates in women of childbearing age with GIO,55 56  
given that bisphosphonates have an extended half-life and may cross the placenta with 
potentially unfavorable effects on fetal skeletal development. A recent review of 51 human 
cases examining exposure to bisphosphonates before or during pregnancy did not 
demonstrate skeletal abnormalities or other congenital malformations in the infants. Similarly, 
a related case-controlled study suggested that preconceptional and first-trimester use of 
bisphosphonates may pose limited fetal risk57. Saag et al., published a randomized multicenter 
trial to compare use of oral alendronate (10 mg/day) and subcutaneous teriparatide (20 
mg/day) over 18 months in patients with established GIO. The study showed that among 
patients with osteoporosis with a high risk for fracture, the bone mineral density increase in 
patients receiving teriparatide was greater than in those receiving alendronate58. 
7. Conclusion 
Localized bone loss in RA results from the activation of an inflammatory immune response, 
which increases both the number and the activity of osteoclasts.  
Osteoporosis in patients with rheumatoid arthritis is a silent disease that evolves in parallel 
with the underlying disease and gives a sign to exist only after the fracture. patients with 
rheumatoid arthritis are subject to chronic systemic inflammation and a chronic intake of 
corticosteroids. These elements form the basis of the osteoclastic process. The diagnosis and 
prevention becomes necessary to understand in all its aspects, the patient rheumatic disease 
and to avoid untoward developments. Therapy to prevent or reverse this bone loss should 
be directed at the suppression of inflammation, direct inhibition of osteoclastmediated bone 
resorption, or stimulation of osteoblastic bone formation.  
The challenge now is to determine if altering this inflammatory induced bone loss in RA will 
translate into reduced functional disability. The future is promising in this scientific arena. 
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